Michael joined Zacco in 2001 and is a senior partner. He has experience from all aspects of patent prosecution within the technical fields of pharmaceutical chemistry, biochemistry, bio fuels, bioinformatics, pulp and paper and medical technology/devices. Michael is frequently involved with both local and international clients in IP strategies as well as Freedom to operate and IP due diligence projects.
Michael graduated with a Master of Science degree in Chemistry from Umeå University in 1996. From 1996 to 2001 he held various positions in Sweden and Norway, first at Pharmacia UpJohn, and then at the Swedish Institute for Food and Biotechnology. He later worked as a business development manager at CAMO Software in Oslo, focusing on project management, licensing, merger and acquisitions processes. He has been co-author of two scientific publications in the technical area of chemometrics.
Michael has been instrumental in setting up Zacco’s international business and is today responsible for Zaccos business in North America. He is a key person in the development of the leading Scandinavian Zacco team for supplementary protections certificates and he has a comprehensive experience of SPC prosecution in Europe.
Clients acknowledge Michael as a highly appreciated key account manager and he devotes significant time to strategic consulting as well as business advices for his clients.
Michael has held several different management positions within Zacco including being member of the board and holds today a position as business development manager and senior patent attorney.
Michael is a member of Zacco specialist groups for SPC applications, US law and IP Due Diligence. Michael is an authorised patent attorney (Sweden), and a member of the International Association for the Protection of Intellectual Property (AIPPI), the Association of IP Professionals in Swedish Industry (SIPF), SwedenBio and the Association of Swedish Patent Attorneys (SPOF). He is ranked as a recommended individual in the IAM Patent 1000 for 2017 and 2018 issued by Intellectual Asset Management.